A couple of weeks after its approval, Orgovyx (relugolix) is now commercially available in the U.S. for adults with advanced prostate cancer through authorized specialty distributors, the therapy’s developer, Myovant Sciences, has announced. “Myovant has been focused on ensuring access to Orgovyx for men with advanced prostate cancer as quickly as possible following approval, and we are delighted to announce that it is now available,” David Marek, company CEO, said in a press release. Orgovyx…

You must be logged in to read/download the full post.